← Browse by Condition
Medical Condition

locally advanced solid tumor

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for locally advanced solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — locally advanced solid tumor Clinical Trials

How many clinical trials are currently recruiting for locally advanced solid tumor?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for locally advanced solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for locally advanced solid tumor?
locally advanced solid tumor research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a locally advanced solid tumor clinical trial?
Eligibility criteria for locally advanced solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
Yuhan Corporation 1 trial
Nuvalent Inc. 1 trial
Centro di Riferimento Oncologico - Aviano 1 trial

Recruiting Clinical Trials

NCT06975410 Phase 1, Phase 2
Recruiting
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Enrollment
80 pts
Location
South Korea
Sponsor
Yuhan Corporation
View Trial →
NCT05118789 Phase 1, Phase 2
Recruiting
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Enrollment
359 pts
Location
United States, Austr...
Sponsor
Nuvalent Inc.
View Trial →
NCT06028724
Recruiting
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Enrollment
782 pts
Location
Italy
Sponsor
Centro di Riferimento Oncologi...
View Trial →

Related Conditions

metastatic solid tumor (2) egfr overexpression (1) solid tumor (1) advanced solid tumor (1) colon rectal cancer (1) gastric cancer (1) pancreatic cancer (1) bile duct cancer (1) hepatocarcinoma (1) breast cancer (1) ovarian cancer (1) endometrial cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology